Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: A final report

被引:23
|
作者
Cafiero, F
Gipponi, M
Lionetto, R
机构
[1] Natl Inst Canc Res, Div Surg Oncol, I-16132 Genoa, Italy
[2] Natl Inst Canc Res, Direz Sanitaria, Genoa, Italy
关键词
rectum; adjuvant therapy; radiation therapy; chemotherapy; TOTAL MESORECTAL EXCISION; RADIATION-THERAPY; LOCAL RECURRENCE; RADIOTHERAPY; FLUOROURACIL; CHEMOTHERAPY; SPHINCTER; SURGERY;
D O I
10.1002/jso.10261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: A randomised clinical trial was performed in patients undergoing radical surgery for rectal cancer,to compare the efficacy and toxicity of adjuvant postoperative radiation therapy (RT) to sequential RT and chemotherapy (CT) with 5-fluorouracil (5-FU) plus levamisole (LEV). The primary end point was overall survival (OS); secondary end points were disease-free survival (DFS), the rate of loco-regional recurrence, and treatment-related toxicity; the final results of this trial are reported. Methods: Patients in arm I underwent RT (50 Gy) in daily fractions of 2 Gy, 5 days/week for 5 weeks. Patients in arm 11 began with 5-FU (450 mg/sqm/day intravenous (i.v.) bolus, days 1-5) plus LEV (150 mg/day orally, days 1-3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I. The other five cycles of CT (5-FU every 28 days and LEV every 15 days for the length of 5-FU administration) continued after the end of RT if clinical and hemato-biochemical parameters were in the normal range. Results: From May 1992 to December 1998, 218 patients were enrolled into the randomised clinical trial (144 men, 74 women; age range: 28-75, median 64 years). The median follow-up time was 58.1 months (range: 1-3,271 days). No significant difference was observed between the two arms of treatment as regards OS and DFS (P = 0.18 and P = 0.66, respectively). Cox regression analysis for OS confirmed what was observed by univariate analysis for all variables except age. Older age (> 60 years) and pathologic lymph-node involvement defined the subgroups with the worst prognosis. Cox regression analysis for DFS confirmed what was observed by univariate analysis for all variables: the only independent variable in predicting DFS was pathologic lymph-node involvement. Conclusions: Our findings suggest no difference in OS, loco-regional and distant site progressions of postoperative RT alone compared to sequential postoperative RT and CT; notably, this latter regimen was associated with higher toxicity which seriously impaired the patient's compliance to CT. The low loco-regional recurrence rate (9.2%) observed in our patients undergoing postoperative RT alone compared to similarly treated patients in previously performed clinical trials (20-25%) underline the role of radical surgery (mesorectal excision) coupled with a complete postoperative RT regimen. On the other hand, the similar efficacy of these two adjuvant modalities of treatment might be conditioned by both the low compliance (59%) to the CT regimen as well as the sequential, instead of concurrent, schedule of administration of RT and CT, which may have decreased further the expected efficacy of the combined regimen. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 14 条
  • [1] Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer
    Cafiero, F
    Gipponi, M
    Peressini, A
    Bertoglio, S
    Lionetto, R
    JOURNAL OF SURGICAL ONCOLOGY, 2000, 75 (02) : 80 - 88
  • [2] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    Taal, BG
    Van Tinteren, H
    Zoetmulder, F
    BRITISH JOURNAL OF CANCER, 2001, 85 (10) : 1437 - 1443
  • [3] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    B G Taal
    H Van Tinteren
    F A N Zoetmulder
    British Journal of Cancer, 2001, 85 : 1437 - 1443
  • [4] Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer A Randomized Clinical Trial
    Li, Ning
    Zhu, Yuan
    Liu, Lu-Ying
    Feng, Yan-Ru
    Wang, Wen-Ling
    Wang, Jun
    Wang, Hao
    Li, Gao-Feng
    Tang, Yuan
    Hu, Chen
    Liu, Wen-Yang
    Ren, Hua
    Wang, Shu-Lian
    Wang, Wei-Hu
    Song, Yong-Wen
    Liu, Yue-Ping
    Fang, Hui
    Tang, Yu
    Lu, Ning-Ning
    Chen, Bo
    Qi, Shu-Nan
    Liu, Xin-Fan
    Li, Ye-Xiong
    Jin, Jing
    JAMA NETWORK OPEN, 2021, 4 (11) : e2136116
  • [5] Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Beart, Robert W.
    Wozniak, Timothy F.
    Pitot, Henry C.
    Shields, Anthony F.
    Landry, Jerome C.
    Ryan, David P.
    Arora, Amit
    Evans, Lisa S.
    Bahary, Nathan
    Soori, Gamini
    Eakle, Janice F.
    Robertson, John M.
    Moore, Dennis F., Jr.
    Mullane, Michael R.
    Marchello, Benjamin T.
    Ward, Patrick J.
    Sharif, Saima
    Roh, Mark S.
    Wolmark, Norman
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11):
  • [6] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    Schippinger, W
    Jagoditsch, M
    Sorré, C
    Gnant, M
    Steger, G
    Hausmaninger, H
    Mlineritsch, B
    Schaberl-Moser, R
    Mischinger, HJ
    Hofbauer, F
    Holzberger, P
    Mittlböck, M
    Jakesz, R
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1655 - 1662
  • [7] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    W Schippinger
    M Jagoditsch
    C Sorré
    M Gnant
    G Steger
    H Hausmaninger
    B Mlineritsch
    R Schaberl-Moser
    H J Mischinger
    F Hofbauer
    P Holzberger
    M Mittlböck
    R Jakesz
    British Journal of Cancer, 2005, 92 : 1655 - 1662
  • [8] Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial
    Delbaldo, C.
    Ychou, M.
    Zawadi, A.
    Douillard, J. Y.
    Andre, T.
    Guerin-Meyer, V.
    Rougier, P.
    Dupuis, O.
    Faroux, R.
    Jouhaud, A.
    Quinaux, E.
    Buyse, M.
    Piedbois, P.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1208 - 1215
  • [9] A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer
    Bendell, Johanna C.
    Thompson, Dana
    Hemphill, Brian M.
    Wenk, David
    Earwood, Chris
    Lane, Cassie M.
    Kennedy, Andrew
    CANCER INVESTIGATION, 2017, 35 (08) : 535 - 540
  • [10] Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212)
    Ohue, Masayuki
    Fujita, Shin
    Mizusawa, Junki
    Kanemitsu, Yukihide
    Hamaguchi, Tetsuya
    Tsukamoto, Shunsuke
    Noura, Shingo
    Yasui, Masayoshi
    Itoh, Masaaki
    Shiomi, Akio
    Komori, Koji
    Watanabe, Jun
    Akazai, Yoshihiro
    Shiozawa, Manabu
    Yamaguchi, Takashi
    Bandou, Hiroyuki
    Katsumata, Kenji
    Moriya, Yoshihiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (02) : 114 - 121